Raymond J. Andersen
Corporate Officer/Principal at University of British Columbia
Raymond J. Andersen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| University of British Columbia | Corporate Officer/Principal | 01/01/1977 | - |
Career history of Raymond J. Andersen
Former positions of Raymond J. Andersen
| Companies | Position | Start | End |
|---|---|---|---|
| ESSA PHARMA INC. | Director/Board Member | 11/10/2010 | 31/07/2019 |
| Chief Tech/Sci/R&D Officer | 11/10/2010 | 31/07/2019 | |
| Founder | 06/01/2009 | 31/07/2019 | |
| Corporate Secretary | 06/01/2009 | 31/07/2019 | |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Founder | 26/12/2003 | - |
Training of Raymond J. Andersen
| University of Alberta | Undergraduate Degree |
| University of California, Berkeley | Graduate Degree |
| University of California San Diego | Doctorate Degree |
Statistics
International
| Canada | 5 |
| United States | 3 |
Operational
| Founder | 2 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 5 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| Private companies | 1 |
|---|---|
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Raymond J. Andersen
- Experience
